ca102n
Advanced or Metastatic Colorectal Cancer (mCRC)
Holy Stone Healthcare Co., LtdPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
839 Active assets in the Advanced or Metastatic Colorectal Cancer (mCRC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
MARBLE DUST James Varani | Phase 2/3 | BB |
FLUOROURACILUM Washington University School of Medicine | Phase 4 | BB |
PANITUMUMAB M.D. Anderson Cancer Center | Phase 3 | BB |
Cetuximab Shanghai Henlius Biotech | Phase 4 | BB |
View all 50 →
Same molecule, other indications
ca102n is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →